Cambrex is an innovative life sciences company with a refreshingly human approach to the way we do business. Our pharmaceutical products, technologies and expertise accelerate your small molecule therapeutics into the market.Learn more
Cambrex has announced that it has completed the acquisition of Avista Pharma Solutions, a contract development, manufacturing, and testing organization, from Ampersand Capital Partners. The transaction, announced on November 20, 2018, strengthens Cambrex’s position as the leading, fully integrated small molecule contract development and manufacturing organization (CDMO) across the entire drug lifecycle.Learn more
Active Pharmaceutical Ingredients and dynamic people come together to create the Cambrex effect. Watch our video to learn how we can accelerate your small molecule therapeutics into the market.
Cambrex is a leading global supplier of more than 90 generic APIs.
With API R&D and cGMP facilities in the USA and Europe, Cambrex can support your project in regulated, emerging and developing markets. We are in your neighbourhood, wherever you are.See our facilities